ARQT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Arcutis Biotherapeutics Inc (ARQT) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows a positive long-term outlook with strong analyst ratings, a bullish technical setup, and promising financial growth in revenue. Despite short-term volatility and mixed sentiment in options data, the company's fundamentals and growth trajectory make it a suitable choice for long-term investment.
The technical indicators for ARQT are moderately bullish. The MACD is positive at 0.26, indicating upward momentum, though it is contracting. The RSI is neutral at 52.051, suggesting no overbought or oversold conditions. Moving averages are bullish with SMA_5 > SMA_20 > SMA_200. Key support and resistance levels are Pivot: 24.209, R1: 25.166, S1: 23.252, R2: 25.757, S2: 22.661.
Analysts have consistently raised price targets to $34-$35, citing strong Q4 results and increased revenue guidance for
Revenue grew significantly by 81.48% YoY in Q4 2025, showing strong growth potential.
Gross margin improved to 90.97%, indicating efficient cost management.
Net income and EPS dropped significantly YoY in Q4 2025, reflecting profitability challenges.
Options data shows mixed sentiment with a high Put-Call Volume Ratio of 1.0, suggesting uncertainty among traders.
Stock trend analysis indicates potential short-term declines (-1.49% in the next week, -3.67% in the next month).
In Q4 2025, the company reported revenue growth of 81.48% YoY to $129.5M, showcasing strong top-line performance. However, net income dropped significantly by -261.24% YoY to $17.4M, and EPS fell by -255.56% YoY to 0.14, indicating profitability challenges. Gross margin improved slightly to 90.97%, reflecting operational efficiency.
Analysts are highly optimistic about ARQT, with multiple firms raising price targets to $34-$35 and maintaining Buy or Outperform ratings. Analysts are encouraged by the company's strong Q4 results, increased revenue guidance, and the commercialization trajectory of its product Zoryve.
